Human endogenous retroviruses as epigenetic therapeutic targets in TP53-mutated diffuse large B-cell lymphoma.

ABSTRACT: TP53 mutation (TP53^mut) occurs in 10-20% of diffuse large B-cell lymphoma (DLBCL) cases and serves as an unfavorable biomarker of DLBCL progression. It confers resistance to immunochemotherapy, high-dose chemotherapy, autologous stem cell transplantation, and anti-CD19 chimeric antigen receptor T-cell therapy. Therapeutic targeting of TP53^mut remains a significant challenge in DLBCL treatment. Here we assessed TP53^mut in 667 patients with newly diagnosed DLBCL, including 576 patients treated with immunochemotherapy rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and 91 patients with decitabine plus R-CHOP (DR-CHOP, NCT02951728 and NCT04025593). TP53^mut independently predicted an inferior prognosis in R-CHOP-treated

SUBMITTER: Fang Y 

PROVIDER: S-EPMC10556001 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature